Direkt zum Inhalt
Merck

Synthesis and biological evaluation of new ligustrazine derivatives as anti-tumor agents.

Molecules (Basel, Switzerland) (2012-05-02)
Penglong Wang, Gaimei She, Yanan Yang, Qiang Li, Honggui Zhang, Jie Liu, Yinqiu Cao, Xin Xu, Haimin Lei
ZUSAMMENFASSUNG

To discover new anti-cancer agents with multi-effect and low toxicity, a series of ligustrazine derivatives were synthesized using several effective anti-tumor ingredients of Shiquandabu Wan as starting materials. Our idea was enlightened by the "combination principle" in drug discovery. The ligustrazine derivatives' anti-tumor activities were evaluated on the HCT-8, Bel-7402, BGC-823, A-549 and A2780 human cancer cell lines. In addition the angiogenesis activities were valued by the chick chorioallantoic membrane (CAM) assay. 1,7-bis(4-(3,5,6-Trimethylpyrazin-2-yl)-3-methoxyphenyl)-1,6-heptadiene-3,5-dione (4) and 3 α,12 α-dihydroxy-5β-dholanic acid-3,5,6-trimethylpyrazin-2-methyl ester (5) not only displayed antiproliferative activities on these cancer cells, but also dramatically suppressed normal angiogenesis in CAM. The LD₅₀ value of the compound 5 exceeded 3.0 g/kg by oral administration in mice.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
2,3,5,6-Tetramethylpyrazin, natural, ≥98%, FG
Sigma-Aldrich
2,3,5,6-Tetramethylpyrazin, 98%
Sigma-Aldrich
2,3,5,6-Tetramethylpyrazin, ≥98%, FG
Supelco
2,3,5,6-Tetramethylpyrazin, analytical standard